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Abstract  
Collagen plays a key role in normal and malignant tissue homeostasis. While the prognostic significance of 
collagen fibre remodeling in invasive breast cancer has been studied, its role in ductal carcinoma in situ 
(DCIS) remains poorly defined. Using image analysis, we aimed to evaluate the prognostic significance of 
the geometric characteristics of collagen surrounding DCIS. A large well-characterized cohort of DCIS 
comprising pure DCIS (n=610) and DCIS co-existing with invasive carcinoma (n=180) were histochemically 
stained for collagen using picrosirius red. ImageJ software was used to assess collagen density, degree of 
collagen fibre dispersion and directionality in relation to DCIS ducts’ boundary. We developed a collagen 
prognostic index and evaluated its prognostic significance. A poor index was observed in 24% of the pure 
DCIS and was associated with determinants of high-risk DCIS including higher grade, comedo necrosis, 
hormonal receptor negativity, HER2 positivity and high proliferation index. High index was associated with 
overexpression of the collagen remodeling protein prolyl-4-hydroxlase alpha 2 and the hypoxia inducible 
factor 1α. DCIS co-existing with invasive carcinoma had a higher collagen prognostic index than pure DCIS 
(p<0.0001). High index was an independent poor prognostic factor for all DCIS recurrences (HR=2.3, 
p=0.005) and just invasive recurrences (HR=3.4, p=0.003). Interaction with radiotherapy showed that the 
higher index was associated with poor outcome even with adjuvant radiotherapy (p=0.0001). In conclusion, 
collagen re-organization around DCIS is associated with poor outcome and provides a potential predictor for 
disease progression and resistance to radiotherapy. Mechanistic studies are warranted to decipher the 
underlying mechanisms.  
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Introduction 
The key difference between invasive breast cancer and ductal carcinoma in situ (DCIS) is the destruction of 
the surrounding basement membrane and invasion of the malignant cells into the surrounding stroma 
accompanied by desmoplastic reaction. However, studies have shown that changes in the surrounding tumor 
microenvironment including infiltrating immune cells, stromal cells and extracellular matrix composition 
occurs early in carcinogenesis much before malignant cells invade the surrounding stroma (1-5). More so, 
these changes may provide a surrogate to predict tumor behavior and potential outcomes (5-7). One of the 
major limitations of currently available clinicopathological indices and molecular signatures to predict DCIS 
risk is the underestimated role of microenvironmental factors. Therefore, despite advances in management 
modalities, a considerable percentage of DCIS are either over- or under-treated. In addition, most molecular 
studies that compared the genetic profiles of DCIS and invasive breast cancer report a high degree of 
similarity (8, 9), creating a compelling need to decipher the role of the tumor microenvironment in DCIS 
behavior.       
Collagen is the main constituent of extracellular matrix and plays a crucial role in tissues homeostasis (10). 
There are many types of collagen with varied localizations and functions in normal and pathological 
conditions (2, 10). The role of collagen in cancer development is not solely related to its chemical 
composition or signaling interaction but is mainly linked to its physical properties and geometric 
characteristics in relation to the tumor cells (4, 11-13). Recent advances in imaging techniques and specific 
histochemical staining of collagen have spurred an increased interest to discover its physical roles and 
biological functions (12, 14-16). In invasive cancers including breast cancer, studies have shown that 
densely aligned collagen is associated with poor outcome and various tumor-associated collagen signatures 
have been described to assess the collagen organization surrounding invasive breast cancer (11). There is 
a dearth of studies deciphering the role of collagen in DCIS; hence more investigations are needed to 
evaluate its prognostic significance. While an earlier study has shown association of aligned collagen with 
other determinants of DCIS aggressive behavior, no statistically significant association with disease 
recurrence or progression was reported (6). In the current study, we hypothesized that collagen re-
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organization surrounding DCIS is linked to aggressive behavior. We have developed an imaged-based 
collagen prognostic index that relies on three factors: the directionality of collagen fibre relative to DCIS 
boundary, collagen density and dispersion using a large cohort of DCIS. 
 
MATERIAL AND METHODS 
 
Study Cohort  
A large well-characterized and annotated cohort of DCIS including pure DCIS (n=776) and DCIS mixed with 
invasive breast cancer (DCIS-mixed) (n=239) diagnosed between 1990 to 2012 at Nottingham City Hospital, 
Nottingham, United Kingdom was used (17). To avoid selection bias, the DCIS-mixed cohort was selected 
with clinicopathological features comparable to the pure cohort regarding age at diagnosis, DCIS nuclear 
grade, and the presence of comedo type necrosis. All demographic, clinical, histological, management 
information was collected. Breast conserving surgery was the primary surgical option for 70% of cases, 
however due to close or positive surgical margins a considerable percentage of patients underwent 
completion mastectomy; half of the cases were treated by mastectomy as the final operation. Data about 
the molecular classes, tumor infiltrating lymphocytes density (7), as well as the key regulator of collagen 
biosynthesis and remodeling prolyl-4-hydroxlases alpha subunit 2 (10) and the hypoxia related marker 
hypoxia inducible factor 1α were available. In brief, the molecular classes were defined based on the 
immunohistochemistry using estrogen (ER) and progesterone (PR) receptor, the human epidermal growth 
factor receptor 2 (HER2) and Ki67 proliferation index. ER and PR were considered positive if >1% of tumor 
cells showed nuclear staining (18) while HER2 positivity was defined when more than 10% of tumor cells 
showed strong complete membranous staining (+3 score). Chromogenic in situ hybridisation was used to 
determine the gene amplification status in borderline cases (+2 score) (19). The proliferation index was 
defined as low when <14% of cells showed nuclear staining for Ki67 (20). Hypoxia inducible factor 1α was 
evaluated using immunohistochemistry and was considered positive when >1% of tumor cells showed 
nuclear staining as previously described (21). Dense tumor infiltrating lymphocytes DCIS was defined in 
DCIS as an average number of ≥20 lymphocytes/duct (7). Follow up data was collected and local recurrence 
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free interval was defined as the time (in months) between 6 months after the primary DCIS excision and 
the development of ipsilateral recurrence (either as DCIS or invasive breast cancer). Cases undergoing 
completion re-excision due to margins’ involvement or presence of residual tumor within the first six months 
of the primary operation were not considered as disease recurrence. Contralateral disease following DCIS 
diagnosis was not accounted as a recurrence and these patients were censored at the time of the 
development of the contralateral cancer. Within a median follow up period of 103 months (range 6-240), 
83 cases (11%) developed a recurrence in the pure DCIS cohort with 30 DCIS (36%) and 53 invasive 
recurrence (64%) (10, 22). Most recurrences (n=66) developed in patients treated with breast conserving 
surgery alone.  
 
Histochemical collagen staining with picrosirius red  
Tissue microarrays were prepared from both cohorts as previously described (17). Briefly, 1 mm punch sets 
were used to construct the tissue microarray using an automated GRAND MASTER 2.4-UG-EN tissue 
microarray machine. For better representation of cases with heterogeneous DCIS histological patterns 
and/or nuclear grade, multiple cores were sampled from all representative areas. 
Picrosirius red solution was prepared by mixing 0.5 g of Sirius Red [Direct red 80, Cat#365548, Sigma-
Aldrich, Darmstadt, Germany] with 500 ml of saturated aqueous solution of picric acid [Cat# P6744-1GA, 
Sigma-Aldrich, Darmstadt, Germany]. Briefly, tissue microarrays sections (4 µm) were deparaffinized and 
rehydrated and immersed in the picrosirius red solution for 60 minutes. Physical removal of excess stain 
was carried out by vigorous slide shaking followed by gentle blotting against soft filter paper. Slides were 
washed in two changes of acidified water, dehydrate in three changes of 100% ethanol, cleared in xylene, 
mounted and cover-slipped. Using light microscopy, epithelial cells were stained yellow while the collagen 
fibres stained red.  
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Image acquisition  
The stained tissue microarrays were scanned using a high-resolution digital scanner (NanoZoomer; 
Hamamatsu Photonics, Welwyn Garden City, UK), at 20× magnification. For obtaining the images for 
subsequent analysis, individual tissue spots were exported as JPEG (8-bit) files at ×20 magnification (1368 
× 768 pixels). Multiple spots were exported for each core to represent the whole tissue. To improve the 
reliability of the study, cores with less than 15% area of stroma were excluded from the analysis. All 
excluded cases were unbiased with respect to clinicopathological features.  
 
Image analysis 
The image analysis was carried out using the Fiji package of ImageJ (NIHR public domain) which is available 
for free download at (https://imagej.nih.gov/ij/download.html). Individual tissue spot JPEG files were 
imported into ImageJ and was split into RBG (Red, Blue, Green) channels. The image segmentation of tumor 
from stroma was carried out on the green color space; the red and blue channels were discarded. The 
segmentation to identify objects of interest was carried out by adjusting the greyscale data to a binary 
image with foreground pixels of interest set to red (pixel signal intensity of 0) and background pixels set to 
white (maximum 8-bit intensity of 255). The pixel intensity threshold for classifying all pixels as either 
foreground or background was defined automatically using the ImageJ histogram thresholding feature. To 
decease background noise, all images were adjusted to threshold of 150. Fields of interest (specialised 
stromal collagen surrounding DCIS ducts) (23) were identified by manually delineating of multiple squares, 
400x400 µm each in dimension (i.e. equivalent to 2-high power fields of the surrounding collagen), with 
their bases touching and parallel/tangential to the duct boundary at the area of contact. Several non-
overlapping areas were marked per image to segment the surrounding stroma resulting in >100 fields 
(average 120 fields) of interest were delineated per each core. Features were extracted by measuring the 
pixel numbers for any particles in the final image using the automated tools in ImageJ. Features extracted 
included the directionality of collagen fibres, i.e. the angle of the adjacent collagen fibres in each square 
relative to the angle of the tangent (duct boundary); collagen fibres dispersion, i.e. the arrangement of fibres 
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relative to each other; and solidity representing the collagen density. Data were recorded in degree (o) for 
directionality and dispersion while pixels were used for solidity measurement. Each field of interest was 
analyzed separately and the average reading for each tissue core was considered as the final score for 
analysis.  Moreover, cases with multiple cores were scored and the average of the final scores for each core 
were used for the analysis. Figure 1 and Supplementary Figures 1 show a schematic representation of the 
image analysis process.  
 
Calculation of collagen prognostic index score 
Each parameter was categorized into three scores (1, 2 and 3) using cut-offs generated from X-tile 
bioinformatics software (Yale University, version 3.6.1) (24) based local recurrence free interval in the pure 
DCIS cohort (Supplementary table 1). Score 3 directionality indicated more perpendicular collagen fibres to 
duct boundary, Score 3 solidity related to dense collagen fibres while Score 3 dispersion referred to lower 
degree of collagen fibre dispersion i.e. collagen fibres parallel to each other. Collagen prognostic index was 
calculated according to the equation;  
 
Collagen prognostic index=collagen directionality score (1-3) + collagen solidity score (1-3) + collagen 
dispersion score (1-3) 
The generated score range was 3-9, and was divided into three prognostic groups based on X-tile software 
whereby a score of 3 or 4 is the good prognostic group, 5-7 for intermediate and score 8 or 9 indicates the 
poor prognostic group (Supplementary Table 1) 
 
Statistical analysis 
Statistical analyses were performed using SPSS v21 (Chicago, IL, USA) for Windows. Spearman’s Rho test 
was used to correlate between the different assessed parameters. Association between collagen prognostic 
index and its different parameters and clinicopathological parameters was performed using Chi-square, 
Mann Whitney and Kruskal-Wallis tests (for categorical and numerical data respectively). Univariate survival 
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analysis against local recurrence free interval was carried out using log rank test and Kaplan Meier curves. 
Cox regression model was used for multivariate analysis and to evaluate the interaction between 
radiotherapy and collagen prognostic index regarding the recurrence. For all tests, a two-tailed p-value of 
less than 0.05 was considered as statistically significant. 
 
This work obtained ethics approval by the North West – Greater Manchester Central Research Ethics 
Committee under the title; Nottingham Health Science Biobank (NHSB), reference number 15/NW/0685. 
 
 
RESULTS 
Distribution of collagen prognostic index parameters and groups 
The final number of cases suitable for scoring was 424 pure DCIS and 149 DCIS co-existing with invasive 
breast cancer after unbiased exclusion of uninformative cores (lost, folded and those containing <15% 
stroma area). The distribution of collagen prognostic index and the three collagen geometric parameters are 
summarized in Supplementary Table 2.  The median directionality and dispersion angles in the pure DCIS 
were 19.6o (range 1-85) and 16.7o (range 5-58), respectively, while the median solidity was 0.5 (range 
0.001-0.9) and the median collagen prognostic index score was 6 (range 3-9). The distribution of all 
parameters was unimodal. The poor collagen prognostic index group represented 24% of the cohort with a 
similar percentage of DCIS in the good prognostic group (23%). Figure 2 shows various patterns of collagen 
arrangement surrounding DCIS. We found a positive linear correlation between high collagen solidity and 
perpendicular or oblique collagen arrangement related to the DCIS ducts’ boundary (r=0.5, p<0.0001, 
Spearman’s correlation). However, the degree of collagen dispersion showed a negative linear correlation 
with both collagen solidity (r=-0.3, p<0.0001, Spearman’s correlation) and directionality (r=-0.3, 
p<0.0001, Spearman’s correlation).  
The proportion of cases with a high collagen prognostic index score (poor prognostic group) was higher in 
DCIS co-existing with invasive breast cancer than pure DCIS (38% and 24% respectively; χ2=36.5, 
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p<0.0001) (Table1). Similar results were observed when the score was analysed using a numerical scale 
(p<0.0001) (Supplementary Table 3). Comparable results were observed for all index parameters whereby 
DCIS co-existing with invasive carcinoma showed a higher extent of perpendicular collagen fibres in relation 
to DCIS boundaries and with collagen fibres more often arranged in parallel (lower dispersion) than pure 
DCIS either in categorical groups or using the numerical scores (Supplementary Tables 4 and 5). The 
proportion of DCIS-coexisting with invasive breast cancer showed denser collagen fibres was slightly higher 
than pure DCIS (58% Vs. 50%) which was not statistically significant (p=0.364). Figure 3 illustrates the 
distribution of collagen prognostic index parameters within pure DCIS and DCIS-invasive breast cancer 
cohorts.    
 
Significance of collagen prognostic index expression in pure DCIS 
Poor collagen prognostic index was associated with other clinicopathological determinants of poor prognosis 
in DCIS (Table1) including higher nuclear grade (p<0.0001), presence of comedo type necrosis (p<0.0001), 
hormonal receptor negativity (p=0.032, p=0.029 for ER and PR, respectively) and HER2 positivity 
(p=0.003). Luminal A DCIS (ER+ and/or PR+, HER2- with <14% proliferation index) had lower collagen 
prognostic index scores where 67% of cases belonged to good prognostic group (p=0.037). Moreover, poor 
collagen prognostic index was associated with other microenvironmental and stromal factors associated with 
poor DCIS prognosis such as dense tumor infiltrating lymphocytes (7) (p=0.016), high levels of prolyl-4-
hydroxlases alpha subunit 2 expression (p<0.0001) which is a collagen remodelling protein which was 
previously reported to be associated with poor outcome in DCIS (10). We validated our results by analyzing 
the numeric collagen prognostic index scores and found comparable results (Supplementary Table 3). 
Furthermore, collagen directionality, dispersion and solidity scores were analysed individually with other 
clinicopathological parameters and the results are summarized in Supplementary Table 4 (for categorical 
groups) and Supplementary Table 5 (for continuous scores).  
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Outcome analysis  
High collagen prognostic index was associated with shorter DCIS local recurrence free interval either for all 
recurrences (DCIS or invasive breast cancer) (HR=2.0; 95%CI=1.3-3.1; p=0.002) and for invasive 
recurrences alone (HR=3.1; 95%CI=1.6-5.5; p=0.0003) (Figure 4). When analysis was confined to patients 
treated with breast conserving surgery, similar results were obtained where poor collagen prognostic index 
was associated with worse outcome for all recurrences (HR=2.1; 95%CI=1.4-3.1; p=0.001) and for invasive 
recurrences (HR=3.0; 95%CI=1.6-5.4; p=0.0003) (Figure 4). Collagen prognostic index was associated 
with poor outcome regardless of the DCIS nuclear grade, whereby poor collagen prognostic index was 
associated with shorter local recurrence free interval either for all recurrences or invasive recurrences only 
(Figure 5) for both high grade DCIS and non-high grade DCIS (low and intermediate DCIS were combined 
together due to the small number of events in the former group). Moreover, evaluation of the interaction 
between collagen prognostic index and radiotherapy (collagen prognostic index*radiotherapy) using a Cox 
regression model showed that higher collagen prognostic index was significantly associated with shorter 
local recurrence free interval even with radiotherapy (HR=1.8, 95%CI=1.3-2.3, p=0.0001). Analysis of the 
individual index parameters (collagen directionality, dispersion and solidity), showed significant associations 
with disease recurrence (Supplementary Figure 2).  Forest plots for univariate analysis of other 
clinicopathological parameters and collagen prognostic index groups and their association with DCIS 
recurrence are shown in Supplementary Figure 3.     
Multivariate survival analysis including the conventional determinants of DCIS risk showed that age at 
diagnosis, nuclear grade, DCIS size, margin status and comedo type necrosis are independent prognostic 
factors for DCIS recurrence. However, when collagen prognostic index was incorporated in the model it was 
the only independent poor prognostic factor for DCIS recurrence in patients treated with breast conserving 
surgery regardless of other known determinants of high-risk DCIS either for all recurrences (HR=2.3, 95% 
CI=1.3-4.2; p=0.005) or invasive recurrences only (HR=3.4, 95% CI=1.5-7.6; p=0.003) (Table 2). 
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DISCUSSION  
Precise assessment of DCIS risk is still challenging despite advances in high throughput molecular 
techniques. None of the currently available clinicopathological based nomograms and indices (25-28) or 
molecular signatures such as Oncotype DX DCIS (29) provide a reliable and clinically valid tool to predict 
DCIS risk of progression and/or recurrence to improve personalised management. The biological and clinical 
heterogeneity of DCIS coupled with underestimation of the important role of the tumor microenvironment 
in disease behavior are potential reasons for this lack of accuracy. Cancer is not exclusively a disease of 
malignant cells, but also involves crosstalk between tumor, stromal cells and other components of the 
surrounding microenvironment. Thus, studying the role of DCIS microenvironment and its interaction with 
the tumor cells could resolve the DCIS management dilemma and provide an adequate and reliable risk 
stratification model (1, 5, 30-32). 
Extracellular matrix and its main constituent, collagen, plays a key role in normal mammary gland 
development (33). Interestingly, increased breast tissue density, caused mainly by increased collagen 
deposition, is a strong risk factors for breast cancer development with high breast density carrying a two- 
to six-fold increase in breast cancer risk compared to women with normal breast density which is almost as 
high a risk factor as BRCA1 and BRCA2 mutations (4, 34). It is reported that DCIS arises more commonly 
in dense regions of the breast (4, 35). While was thought that collagen provided a natural physiological 
barrier against tumor invasion, recent studies have provided concrete evidence on the key role of that 
collagen dynamic changes (collagen deposition, degradation, re-organization and remodelling) in 
carcinogenesis, tumor maintenance and progression through its role in cellular adhesion, proliferation, 
migration, invasion and angiogenesis (36). A recent genetic study showed that extracellular matrix re-
organization and response to cellular stress are key factors in breast cancer progression (37). Several 
studies on invasive breast cancer and other types of cancer using second harmonic generation microscopy 
or multiphoton laser scanning showed that organization of collagen around malignant tissues provides a 
tumor associated collagen signature that is associated with tumors behavior and patients’ outcome (2, 4, 
13). Given that, the role of collagen remodeling in DCIS behavior is relatively understudied, we evaluated 
the collagen fibre organization surrounding DCIS and its prognostic significance. We have used a novel 
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imaging method, to the best of our knowledge, to assess collagen characteristics in a large cohort of DCIS 
and have developed a collagen prognostic index to predict the risk of DCIS recurrence and progression.   
In this study, we examined the density and arrangement of collagen relative to each other and the boundary 
of DCIS. Interestingly, higher collagen prognostic index was associated with features of high-risk DCIS 
including higher nuclear grade, comedo type necrosis, hormonal receptor negativity and HER2 positivity, 
supporting its role in DCIS progression. Additionally, our data showed that collagen prognostic index was 
higher in DCIS co-existing with invasive breast cancer than pure DCIS. Taken together, collagen re-
organization is a potential factor for high risk DCIS. The poor prognostic value of collagen rearrangement 
was shown with a shorter local recurrence free interval in patients with higher levels of collagen prognostic 
index independently from other clinicopathological factors. These findings were consistent for all recurrent 
events, either DCIS or invasive breast cancer or when the analysis was confined to invasive recurrences 
only, which provides more evidence that collagen rearrangement and deposition could play a key role in 
DCIS progression to invasive disease. collagen prognostic index could predict the risk of recurrence in non-
high grade DCIS, which is a group at risk of under-treatment due to the lack of accurate predictors of 
recurrence in this group, although genetic studies showed that the DCIS are the precursors of low grade 
invasive breast cancer. Hence, collagen prognostic index could drive the management decision is these 
patients. The poor prognostic group of non-high grade DCIS had a 22% risk of invasive recurrence within 
10 years, compared to zero invasive recurrences in the good prognostic group.   
  
Although the effect of radiotherapy  in reduction of DCIS recurrence is undeniable (38-41), there is still a 
considerable percentage of patients treated with breast conserving surgery and followed by adjuvant 
radiotherapy  that develop disease recurrence. There is no data available for DCIS patients at higher 
susceptibility for poor response to radiotherapy. Our findings showed that DCIS with a high collagen 
prognostic index is associated with poor outcome even when radiotherapy was offered. This index could 
provide a signature for radiotherapy resistance in DCIS. It is reported that dense stroma is associated with 
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poor response to radiotherapy  in cancer treatment (42) which might provide a similar explanation in DCIS. 
These findings need mechanistic studies for validation.    
Although the mechanisms that lead to collagen changes and how these changes affect tumor behavior are 
not fully understood, several explanations are available. Tumor cells could secret factors that realign a 
random collagen matrix into a radially arranged collagen to facilitate local invasion (13). The role of hypoxia 
and collagen remodeling proteins such as prolyl-4-hydroxlases alpha subunit 2 and lysyl oxidase are obvious 
in developing collagen signatures as shown from previous studies and our findings in the current study (10, 
43). As a reciprocal effect, collagen density can affect tumor growth even in tumor harboring scanty stroma. 
Cells cultured within low-density matrices form well-differentiated acini structures, while colonies that 
formed within high-density matrices are larger, more proliferative and less organized structures indicating 
that increasing collagen matrix density can directly promote epithelial cell proliferation (4).  
Stiffer extracellular matrix due to increased collagen deposition results in high local mechanical loads and 
higher resistance to cellular contractility (4). Such changes in the physical microenvironment lead to loss of 
cellular adhesion, increase tumor cells proliferation and promotes a transformed phenotype.  These findings 
are supported from our results where higher collagen solidity and lower collagen dispersion were associated 
with a higher proliferation index. Moreover, stromal fibroblasts can regulate epithelial cells in part through 
secretion of specific soluble growth factors and chemokines such as tumor growth factor β that has been 
associated with reactive stroma and fibrosis, while studies indicate that the epidermal growth 
factors/receptors (i.e.HER2) are important not only in the normal mammary gland but also during 
tumorigenesis and metastasis (44, 45). These findings are supported from our results where higher collagen 
prognostic index was associated with HER2 overexpression and higher proliferation index.  
Mechanical forces can induce epithelial mesenchymal transition leading to tumor invasion (2). With the 
tumor mass increasing, stress on extracellular matrix increases correspondingly until reaching a critical 
point, the biomechanical trigger, which can be sensed by mechanical receptors in both tumor and stromal 
cells. In turn these cells exert cytoskeletal-dependent traction forces on the extracellular matrix (13, 46, 
47). Eventually, tumor and stromal cells deform as consequences of the altered tissue tension (48, 49), the 
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expanding tumor mass (50), matrix stiffening (51), and increased interstitial pressure due to a leaky 
vasculature and poor lymphatic drainage, initiating epithelial mesenchymal transition (52). These deformed 
cells acquire a more spindle-like fibroblastic morphology, lower adhesive properties, enhanced motility and 
invasive behavior. Studies showed that local invasion in stroma rich areas is due an intrinsic property of 
tumor cells arising in a collagen-dense stroma rather than being a simple reflection of increased local 
collagen that facilitates invasion. Tumor cells isolated from collagen-dense tissues were in fact innately more 
migratory, indicating that the ease of invasiveness facilitated by certain collagen structures is likely not the 
sole cause for increased metastasis but that the tumor cells themselves are more invasive (4). Moreover, 
aligned collagen provides an adhesive scaffold that support tumor cells in their invasion and migratory 
process (6, 11-13, 16).  Mechanical forces also activate sites on collagen to recruit monocytes leading to a 
cascade of innate immuno-inflammatory reactions (2). Our results showed that dense collagen is associated 
with denser tumor infiltrating lymphocytes than lesions with scanty and randomly distributed stromal 
collagen. The underlying biology warrants an investigation, given our previous report that dense tumor 
infiltrating lymphocytes have poor prognostic significance in DCIS, a reverse phenomenon to that in invasive 
disease for which the underlying mechanisms are unclear (7).   
 
This study has been carried out on tissue microarray without including full face sections, which might 
underestimate the role of DCIS heterogeneity. However, all cases in our cohort were histologically reviewed 
before tissue microarray construction and multiple cores were used for cases with heterogeneous grade or 
morphological patterns. Also, our cohort did not include patients treated with endocrine therapy 
 
In conclusion, collagen prognostic index could provide a signature for prediction of DCIS recurrence risk. 
Collagen deposition and re-organization around DCIS plays a role in tumor progression and recurrence. 
Collagen features are stable and robust, persisting even when tissues have not been properly fixed, and 
these features are maintained under various tissue-processing approaches. Thus, picrosirius staining of 
collagen and subsequent image analysis to assess collagen prognostic index could readily be used in clinical 
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practice and could drive DCIS management decisions. Additional functional studies to delineate the 
mechanistic role of collagen re-organization in DCIS behavior are warranted.  
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Figures legends: 
 
 
Figure 1: Diagram shows the different parameters assessed to evaluate the collagen characteristics 
surrounding DCIS. Green squares refer to the fields of interest for analysis (400x400 µm surrounding the 
DCIS boundary and note that all squares are aligned touching and parallel to imaginary tangential line to 
the duct boundary. A) Perpendicularly arranged collagen fibres relative to duct boundary, B) Parallel 
arranged fibres towards the duct boundary, C) Collagen fibres arranged parallel to each other (lower 
dispersion) while D) randomly arranged fibres (higher dispersion). E) Dense collagen fibres and F) scanty 
collagen fibres. During the analysis the 3 parameters were assessed per each field of interest (square) and 
the final average value was used in the analysis.  
 
Figure 2: Example of collagen fibre arrangement in 2 DCIS cases. A and B represent a case surrounded by 
dense collagen with lower dispersion (parallelly arranged collagen fibres all over the duct perimetry) and 
different directionalities, where collagen fibres delineated in (B) with black square show parallel arrangement 
relative to duct boundary (The tangential line), the fibres in the green square show more perpendicular 
arrangement relative to the tangential line touching the duct boundary. C and D represent DCIS surrounded 
by scanty randomly distributed collagen fibres with varied directionality relative to tangential line to the duct 
boundary. (A and C are DCIS sections stained with picrosirius red, while B and D are the images generated from ImageJ software). 
 
Figure 3: Violin plots comparing the distribution of collagen prognostic index parameters between pure 
DCIS and DCIS co-existing with invasive carcinoma (mixed DCIS). Obviously, DCIS mixed showed higher 
angle of directionality and lower dispersion degree than pure DCIS. No statistically significant difference 
between collagen density between pure and mixed DCIS. Central line in the boxplot represents the median 
while the error bars represent the standard deviation.  
 
Figure 4: Kaplan Meier curves show that the poor collagen prognostic index group is associated with shorter 
ipsilateral local recurrence free interval for all recurrences (A) and invasive recurrences (B) in the whole 
series as well as in the breast conserving surgery treated group (C; for all recurrences and D; for invasive 
recurrences).  
 
 
Figure 5: Kaplan Meier curves show that poor collagen prognostic index group is associated with shorter 
ipsilateral local recurrence free interval for all recurrences (A) and invasive recurrences (B) in non-high 
grade DCIS as well as in high grade DCIS (C; for all recurrences and D; for invasive recurrences). 
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Table 1: Correlation between collagen prognostic index and clinicopathological parameters in the pure 
DCIS cohort 
Clinicopathological 
Parameters 
Collagen prognostic index groups χ2 
(p-value) 
Good (n=96) Moderate (n=128) Poor (n=100) 
Age (years) 
   ≤50  
   >50  
 
26 (27) 
70 (73) 
 
52 (23) 
176 (77) 
 
30 (30) 
70 (70) 
 
2.1 
(0.356) 
Presentation  
   Screening 
   Symptomatic 
 
45 (47) 
51 (53) 
 
115 (50) 
113 (50) 
 
60 (60) 
40 (40) 
 
3.7 
(0.150) 
DCIS Size (mm) 
   ≤20  
   >20 
 
45 (47) 
51 (53) 
 
90 (40) 
137 (60) 
 
45 (45) 
55 (55) 
 
1.7 
(0.414) 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
39 (41) 
35 (37) 
22 (22) 
 
7 (3) 
64 (28) 
157 (69) 
 
0 (0) 
9 (9) 
91 (91) 
 
155.6 
(<0.0001) 
Comedo necrosis  
   Yes 
   No 
 
41 (43) 
55 (57) 
 
168 (74) 
60 (26) 
 
83 (83) 
17 (17) 
 
42.4 
(<0.0001) 
Estrogen receptor status   
   Negative 
   Positive 
 
15 (17) 
73 (83) 
 
59 (28) 
154 (72) 
 
32 (34) 
62 (66) 
 
6.8 
(0.032) 
Progesterone receptor 
   Negative 
   Positive 
 
28 (32) 
61 (69) 
 
99 (46) 
115 (54) 
 
47 (49) 
49 (51) 
 
7.1 
(0.029) 
HER2 status  
   Negative 
   Positive 
 
79 (86) 
13 (14) 
 
163 (75) 
54 (25) 
 
63 (64) 
35 (36) 
 
11.8 
(0.003) 
Proliferation index (Ki-67) 
   High 
   Low 
 
13 (16) 
68 (84) 
 
49 (24) 
156 (76) 
 
29 (31) 
64 (69) 
 
5.4 
(0.066) 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative 
 
51 (67) 
11 (14) 
6 (8) 
8 (11) 
 
95 (49) 
40 (21) 
32 (17) 
25 (13) 
 
34 (40) 
20 (24) 
19 (22) 
12 (14) 
13.4 
(0.037) 
Tumor infiltrating lymphocytes   
   Dense 
   Sparse  
 
27 (39) 
43 (61) 
 
96 (50) 
96 (50) 
 
53 (62) 
33 (38) 
8.2 
(0.016) 
P4HA2 expression  
   High 
   Low 
 
28 (34) 
54 (66) 
 
127 (62) 
78 (38) 
 
52 (60) 
35 (40) 
19.2 
(<0.0001) 
HIF1α expression  
   High 
   Low 
 
11 (15) 
62 (85) 
 
45 (25) 
137 (75) 
 
23 (30) 
54 (70) 
 
4.7 
0.094 
Tumor Type* 
   Pure DCIS  
   DCIS associated with IBC 
 
96 (97) 
3 (3) 
 
228 (72) 
89 (28) 
 
100 (64) 
57 (36) 
 
36.5 
(<0.0001) 
*Including pure DCIS (n=424) and DCIS coexisting with IBC (n=149) 
Significant p values are in bold 
DCIS; ductal carcinoma in situ, HER2; human epidermal growth factor receptor 2, P4HA2; prolyl-4-hydroxylase alpha 
subunit 2, HIF1α; hypoxia inducible factor-1 alpha, IBC; invasive breast cancer.   
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Table 2: Multivariate survival analysis (Cox regression model) of variables predicting outcome in terms of 
ipsilateral local recurrence (either all recurrences A, or invasive recurrences B) in DCIS patients treated by 
breast conserving surgery. 
 
A) All recurrences  
Conventional clinicopathological parameters associated with high risk DCIS   
Parameters   Hazard 
ratio (HR) 
95% confidence interval (CI)   
p-value 
Lower Upper 
Patient Age 0.4 0.2 0.8 0.006 
DCIS presentation  1.5 0.9 2.4 0.111 
DCIS size 1.5 1.1 2.1 0.040 
DCIS nuclear Grade 1.9 1.3 2.7 0.001 
Comedo necrosis 0.6 0.4 0.9 0.049 
Margin status  0.8 0.7 0.9 0.004 
Collagen prognostic index and other clinicopathological parameters associated with 
high risk DCIS 
Collagen prognostic index 2.3 1.3 4.2 0.005 
Patient Age 0.5 0.2 1.1 0.072 
DCIS presentation  2.1 0.9 4.3 0.052 
DCIS size 0.9 0.5 1.6 0.760 
DCIS nuclear Grade 1.1 0.5 1.9 0.994 
Comedo necrosis 0.8 0.4 1.6 0.559 
Margin status  0.9 0.8 1.1 0.236 
             Significant p values are in bold  
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B) Invasive recurrence  
Conventional clinicopathological parameters associated with high risk DCIS   
Parameters   Hazard 
ratio (HR) 
95% confidence interval (CI)   
p-value 
Lower Upper 
Patient Age 0.5 0.2 1.3 0.156 
DCIS presentation  1.4 0.8 2.6 0.245 
DCIS size 1.8 1.1 2.4 0.013 
DCIS nuclear Grade 1.9 1.1 3.0 0.013 
Comedo necrosis 0.7 0.4 1.3 0.274 
Margin status  0.9 0.8 1.1 0.075 
Collagen prognostic index and other clinicopathological parameters associated with 
high risk DCIS 
Collagen prognostic index 3.4 1.5 7.6 0.003 
Patient Age 1.2 0.4 3.7 0.697 
DCIS presentation  3.0 1.2 7.9 0.025 
DCIS size 1.3 0.7 2.7 0.412 
DCIS nuclear Grade 0.9 0.4 2.3 0.909 
Comedo necrosis 0.9 0.4 2.1 0.786 
Margin status  0.9 0.8 1.1 0.838 
                        Significant p values are in bold  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Supplementary Table 1: Scores of collagen directionality, dispersion, density and collagen prognostic index 
based on cut-off points generated from X-tile software  
 Collagen Directionality Collagen Dispersion Collagen Solidity 
Score 1 2 3 1 2 3 1 2 3 
Threshold <13.6o 13.6 -19.6 o >19.6 o >15.8 o 12.3-15.8 o <12.3 o <0.2 0.2-0.6 >0.6 
Collagen prognostic index (CPI) = Collagen directionality score + collagen solidity score 
+ collagen dispersion score 
 
Collagen prognostic index groups: 
- Good prognostic group: Scores 3 or 4 
- Moderate prognostic group: Scores 5, 6 or 7 
- Poor prognostic group: Scores 8 or 9 
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Supplementary Table 2: Distribution of collagen prognostic index and its parameters scores within the pure 
DCIS cohort  
 Collagen Directionality Collagen Dispersion Collagen Solidity CPI 
Mean ± SD 23.6 ± 17.2  17.8 ± 6.8 0.5 ± 0.3 6 ± 1.8 
Median 19.6 16.7 0.5 6 
Minimum  1.0 5.1 0.001 3 
Maximum 85.0 58.1 0.9 9 
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 Supplementary Table 3: Correlation between collagen prognostic index scores (continuous 
values) and different clinicopathological parameters in the pure DCIS cohort. 
Clinicopathological  
Parameters 
Number of cases 
collagen prognostic index score 
Mean Rank p-value  
Age (years) 
   ≤50  
   >50  
 
108 
316 
 
216.9 
210.9 
0.657 
Presentation  
   Screening 
   Symptomatic 
 
220 
204 
 
224.0 
200.0 
0.042 
DCIS Size (mm) 
   ≤20  
   >20 
 
180 
243 
 
214.2 
210.3 
0.742 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
46 
108 
270 
 
65.8 
155.3 
260.4 
<0.0001 
Comedo necrosis  
   Yes 
   No 
 
292 
132 
 
237.7 
156.9 
<0.0001 
Estrogen receptor   
   Negative 
   Positive 
 
106 
289 
 
221.2 
189.5 
0.013 
Progesterone Receptor 
   Negative 
   Positive 
 
174 
225 
 
215.7 
187.8 
0.015 
HER2 status 
   Negative 
   Positive 
 
305 
102 
 
193.9 
234.0 
0.003 
Proliferation index (Ki-67) 
   High 
   Low 
 
91 
288 
 
218.1 
18611 
0.004 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative 
 
180 
71 
57 
45 
 
160.4 
192.4 
198.6 
191.8 
0.017 
Tumour infiltrating lymphocytes    
   Dense 
   Sparse 
 
176 
172 
 
185.1 
163.7 
 
0.044 
P4HA2 expression  
   High 
   Low 
 
207 
167 
 
206.4 
164.2 
0.0001 
HIF1A expression  
   High 
   Low 
 
79 
253 
 
188.1 
159.5 
0.017 
Tumour Type* 
   Pure DCIS  
   DCIS associated with IBC 
 
424 
149 
 
262.9 
355.6 
<0.0001 
           *Including pure DCIS (n=424) and DCIS coexisting with IBC (n=149) 
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Significant p values are in bold 
DCIS; ductal carcinoma in situ, HER2; human epidermal growth factor receptor 2, P4HA2; prolyl-4-
hydroxylase alpha subunit 2, HIF1α; hypoxia inducible factor-1 alpha, IBC; invasive breast cancer.   
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 Supplementary Table 4: Correlation between collagen prognostic index parameters and different clinicopathological parameters in the pure DCIS cohort. 
 
Clinicopathological  
Parameters 
Collagen Directionality   
(n=424) χ2 
(p-value) 
Collagen Solidity    
(n=424) χ2 
(p-value) 
Collagen Dispersion   
(n=424) χ2 
(p-value) 
Score 1 Score 2 Score 3 Score 1 Score 2 Score 3 Score 1 Score 2 Score 3 
Age (years) 
   ≤50  
   >50  
 
33 (26) 
92 (74) 
 
25 (28) 
64 (72) 
 
50 (24) 
160 (76) 
 
0.6 
(0.710) 
 
25 (26) 
72 (74) 
 
43 (28) 
111 (72) 
 
40 (23) 
133 (77) 
 
0.9 
(0.608) 
 
54 (23) 
179 (77) 
 
21 (22) 
73 (78) 
 
33 (34) 
64 (66) 
 
4.9 
(0.088) 
Presentation  
   Screening 
   Symptomatic 
 
60 (48) 
65 (52) 
 
37 (42) 
52 (59) 
 
123 (59) 
87 (41) 
8.3 
(0.016) 
 
42 (43) 
55 (57) 
 
82 (53) 
72 (47) 
 
96 (56) 
77 (44) 
 
3.8 
(0.144) 
 
116 (50) 
117 (50) 
 
55 (58) 
39 (42) 
 
49 (51) 
48 (49) 
2.1 
(0.343) 
DCIS Size (mm) 
   ≤20  
   >20 
 
54 (44) 
70 (56) 
 
31 (35) 
58 (65) 
 
95 (45) 
115 (55) 
 
2.8 
(0.242) 
 
45 (46) 
52 (54) 
 
65 (43) 
88 (57) 
 
70 (41) 
103 (59) 
 
0.8 
(0.639) 
 
95 (41) 
138 (59) 
 
44 (47) 
50 (53) 
 
41 (43) 
55 (57) 
0.9 
(0.607) 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
30 (24) 
36 (29) 
59 (47) 
 
15 (17) 
16 (18) 
58 (65) 
 
1 (1) 
56 (27) 
153 (72) 
54.5 
(<0.0001) 
 
46 (47) 
44 (44) 
7 (7) 
 
0 (0) 
50 (33) 
104 (67) 
 
0 (0) 
14 (8) 
159 (92) 
 
 
164.2 
(<0.0001) 
 
32 (14) 
84 (36) 
117 (50) 
 
11 (12) 
15 (16) 
68 (72) 
 
3 (3) 
9 (9) 
85 (88) 
47.3 
(<0.0001) 
Comedo necrosis  
   Yes 
   No 
 
73 (58) 
52 (42) 
 
62 (70) 
27 (30) 
 
157 (75) 
53 (25) 
 
9.8 
(0.007) 
 
32 (33) 
65 (67) 
 
114 (74) 
40 (26) 
 
146 (84) 
27 (16) 
 
79.6 
(<0.0001) 
 
144 (62) 
89 (38) 
 
70 (75) 
24 (25) 
 
78 (80) 
19 (20) 
12.8 
(0.002) 
Estrogen receptor status   
   Negative 
   Positive 
 
27 (24) 
87 (76) 
 
30 (36) 
54 (64) 
 
49 (25) 
148 (75) 
4.3 
(0.114) 
 
8 (9) 
83 (91) 
 
48 (33) 
96 (67) 
 
50 (31) 
110 (69) 
 
19.8 
(0.0001) 
 
48 (22) 
166 (78) 
 
23 (26) 
65 (74) 
 
35 (38) 
58 (62) 
7.7 
(0.022) 
Progesterone receptor 
   Negative 
   Positive 
 
48 (41) 
68 (59) 
 
47 (56) 
37 (44) 
 
79 (40) 
120 (60) 
 
6.7 
(0.036) 
 
20 (22) 
72 (78) 
 
73 (50) 
72 (50) 
 
81 (50) 
81 (50) 
 
23.3 
(<0.0001) 
 
82 (38) 
135 (62) 
 
41 (47) 
46 (53) 
 
51 (54) 
44 (46) 
7.3 
(0.025) 
HER2 status  
   Negative 
   Positive 
 
93 (78) 
27 (22) 
 
57 (68) 
27 (32) 
 
155 (76) 
48 (24) 
2.9 
(0.237) 
 
88 (95) 
5 (5) 
 
107 (72) 
41 (28) 
 
110 (66) 
56 (34) 
26.4 
(<0.0001) 
 
175 (79) 
46 (21) 
 
67 (74) 
24 (26) 
 
63 (66) 
32 (34) 
5.9 
(0.051) 
Proliferation index (Ki-67) 
   High 
   Low 
 
23 (21) 
86 (79) 
 
19 (25) 
58 (75) 
 
49 (25) 
144 (75) 
0.7 
(0.696) 
 
11 (13) 
71 (87) 
 
35 (25) 
107 (75) 
 
45 (29) 
110 (71) 
7.2 
(0.027) 
 
37 (18) 
167 (82) 
 
23 (28) 
59 (72) 
 
31 (33) 
62 (67) 
9.1 
(0.011) 
  
 
34 
 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative 
 
58 (56) 
19 (18) 
16 (16) 
10 (10) 
 
31 (42) 
15 (20) 
18 (24) 
10 (14) 
 
91 (52) 
37 (21) 
23 (13) 
25 (14) 
7.2 
(0.303) 
 
59 (76) 
10 (13) 
2 (3) 
6 (8) 
 
61 (47) 
22 (17) 
27 (21) 
19 (15) 
 
60 (41) 
39 (26) 
28 (19) 
20 (14) 
 
32.1 
(<0.0001) 
 
108 (56) 
37 (19) 
23 (12) 
24 (13) 
 
36 (48) 
17 (23) 
13 (17) 
9 (12) 
 
36 (42) 
17 (20) 
21 (24) 
12 (14) 
8.8 
(0.185) 
Tumour infiltrating lymphocytes   
   Dense 
   Sparse  
 
49 (50) 
49 (50) 
 
41 (53) 
36 (47) 
 
86 (50) 
87 (50) 
0.3 
(0.867) 
 
28 (38) 
46 (62) 
 
64 (51) 
61 (49) 
 
84 (56) 
65 (44) 
6.8 
(0.033) 
 
85 (46) 
99 (54) 
 
39 (49) 
41 (51) 
 
52 (62) 
32 (38) 
 
5.8 
(0.054) 
P4HA2 expression  
   High 
   Low 
 
50 (46) 
59 (54) 
 
48 (58) 
34 (42) 
 
109 (60) 
74 (40) 
5.6 
(0.060) 
 
27 (32) 
58 (68) 
 
89 (63) 
53 (37) 
 
91 (62) 
56 (38) 
24.7 
(<0.0001) 
 
99 (49) 
102 (51) 
 
50 (58) 
36 (42) 
 
58 (67) 
29 (33) 
 
7.8 
(0.020) 
HIF1A expression  
   High 
   Low 
 
23 (24) 
72 (76) 
 
20 (28) 
52 (72) 
 
36 (22) 
129 (78) 
0.9 
(0.608) 
 
9 (12) 
69 (88) 
 
26 (21) 
98 (79) 
 
44 (34) 
86 (66) 
14.2 
(0.001) 
 
38 (20) 
149 (80) 
 
16 (22) 
56 (78) 
 
25 (34) 
48 (66) 
 
5.7 
(0.057) 
Tumour Type* 
   Pure DCIS  
   DCIS associated with IBC 
 
125 (98) 
2 (2) 
 
89 (95) 
5 (5) 
 
210 (60) 
142 (40) 
 
97.8 
(<0.0001) 
 
97 (91) 
9 (9) 
 
154 (65) 
82 (35) 
 
173 (75) 
58 (25) 
 
26.4 
(<0.0001) 
 
233 (78) 
65 (22) 
 
94 (67) 
47 (33) 
 
97 (72) 
37 (27) 
 
6.8 
(0.033) 
*Including pure DCIS (n=424) and DCIS coexisting with IBC (n=149) 
Significant p values are in bold 
DCIS; ductal carcinoma in situ, HER2; human epidermal growth factor receptor 2, P4HA2; prolyl-4-hydroxylase alpha subunit 2, HIF1α; hypoxia inducible factor-1 alpha, 
IBC; invasive breast cancer.  
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Supplementary Table 5: Correlation between different collagen prognostic index parameters and 
clinicopathological parameters in the pure DCIS cohort using continuous data.  
Clinicopathological  
Parameters 
Number of 
cases 
Collagen Directionality   Collagen Solidity    Collagen Dispersion     
Mean Rank p-value Mean Rank p-value Mean Rank p-value 
Age (years) 
   ≤50  
   >50  
 
108 
316 
 
210.2 
213.3 
0.822 
 
201.7 
216.2 
0.286 
 
198.3 
217.4 
0.162 
Presentation  
   Screening 
   Symptomatic 
 
220 
204 
 
225.0 
199.0 
0.029 
 
225.2 
198.8 
 
0.027 
 
211.4 
213.8 
 
0.840 
DCIS Size (mm) 
   ≤20  
   >20 
 
180 
243 
 
216.9 
208.4 
0.482 
 
207.2 
215.5 
0.489 
 
213.7 
210.7 
0.801 
Nuclear Grade 
   Low 
   Moderate 
   High 
 
46 
108 
270 
 
83.0 
192.2 
242.7 
<0.0001 
 
31.4 
134.2 
274.7 
<0.0001 
 
249.1 
264.2 
185.6 
<0.0001 
Comedo necrosis  
   Yes 
   No 
 
292 
132 
 
227.0 
180.4 
0.0002 
 
244.8 
140.9 
<0.0001 
 
202.7 
234.2 
0.014 
Estrogen receptor   
   Negative 
   Positive 
 
106 
289 
 
200.7 
197.0 
0.776 
 
230.4 
186.1 
0.001 
 
175.7 
206.2 
0.019 
Progesterone Receptor 
   Negative 
   Positive 
 
174 
225 
 
197.7 
201.8 
0.722 
 
226.3 
179.6 
<0.0001 
 
185.7 
211.1 
0.029 
HER2 status 
   Negative 
   Positive 
 
305 
102 
 
199.5 
217.4 
0.183 
 
189.2 
248.3 
<0.0001 
 
210.5 
184.6 
0.055 
Proliferation index (Ki-67) 
   High 
   Low 
 
91 
288 
 
200.6 
186.7 
0.290 
 
211.8 
183.1 
0.029 
 
161.7 
198.9 
0.005 
Molecular classes 
   Luminal A 
   Luminal B 
   HER2 Enriched  
   Triple negative 
 
180 
71 
57 
45 
 
171.5 
186.4 
175.8 
185.6 
0.694 
 
153.9 
198.8 
208.2 
195.5 
0.0001 
 
186.6 
176.8 
148.6 
174.7 
0.109 
Tumour infiltrating lymphocytes    
   Dense 
   Sparse 
 
176 
172 
 
175.2 
173.7 
 
0.892 
 
187.3 
163.3 
 
0.016 
 
165.1 
184.2 
 
0.075 
P4HA2 expression  
   High 
   Low 
 
207 
167 
 
197.4 
175.2 
0.048 
 
205.6 
165.1 
<0.0001 
 
175.3 
202.7 
0.015 
HIF1A expression  
   High 
   Low 
 
79 
253 
 
168.1 
166.0 
0.865 
 
198.9 
156.4 
0.001 
 
146.9 
172.6 
0.038 
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Tumour Type* 
   Pure DCIS  
   DCIS associated with IBC 
 
424 
149 
 
225.8 
461.3 
<0.0001 
 
283.3 
297.6 
0.364 
 
298.6 
254.0 
0.005 
*Including pure DCIS (n=424) and DCIS coexisting with IBC (n=149) 
Significant p values are in bold 
DCIS; ductal carcinoma in situ, HER2; human epidermal growth factor receptor 2, P4HA2; prolyl-
4-hydroxylase alpha subunit 2, HIF1α; hypoxia inducible factor-1 alpha, IBC; invasive breast 
cancer.   
 
